德拉沙星作为一种新型广谱抗生素，对革兰氏阳性菌(G+)、革兰氏阴性菌(G-)以及厌氧菌均显示广泛而 强大的抗菌活性。与其他氟喹诺酮类抗菌药物相比，德拉沙星具有阴离子特性，能够增强酸性环境中的 抗菌活性，且在酸性环境下的药物累积量可达其他氟喹诺酮类药物的10倍，对甲氧西林耐药金黄色葡萄 球菌(MRSA)以及其他病原菌的抗菌活性更强。德拉沙星具有新型结构特征，抗菌活性显著增强且不易 耐药，其临床疗效和安全性已获国内外临床研究实践验证，是目前唯一被美国外科感染学会(SIS)《复 杂皮肤软组织感染的管理指南》纳入推荐用于MRSA治疗的喹诺酮类药物，与传统喹诺酮类药物不推荐 用于MRSA感染形成显著差异。其安全性良好，相关治疗未见QT间期延长、光毒性等传统喹诺酮类药 物常见风险的报道。 智通财经APP讯，奥赛康(002755.SZ)发布公告，公司全资子公司江苏奥赛康药业有限公司(以下简称"子 公司")于近日收到国家药品监督管理局(以下简称"药监局")核准签发的注射用德拉沙星葡甲胺《药品注 册证书》。 ...

Core Insights - Researchers from Canada and the United States have discovered a new broad-spectrum lasso peptide antibiotic that targets bacterial ribosomes, showing efficacy against various pathogenic bacteria, including drug-resistant strains, providing a new avenue to address antibiotic resistance [1][2] Group 1: Discovery and Mechanism - The compound, named lariocidin, was identified from soil samples collected by a laboratory technician and exhibits strong antibacterial activity against Escherichia coli [1] - Lariocidin targets the bacterial ribosome, disrupting protein synthesis, which inhibits bacterial growth and reproduction, and has a low tendency to develop resistance due to its different mechanism of action compared to conventional antibiotics [2] Group 2: Efficacy and Safety - Animal studies demonstrated that lariocidin is highly effective against Acinetobacter baumannii, a strain resistant to carbapenem antibiotics [2] - No evidence of toxicity to human cells was found, indicating a potential safety profile for future clinical applications [2] Group 3: Public Health Implications - Antibiotic resistance poses a significant global public health challenge, with approximately 1.1 million deaths in 2021 linked to bacterial resistance to antibiotics [2] - The research suggests that lariocidin could serve as a chemical scaffold for developing urgently needed new antibiotics, although further studies are required to understand its metabolism and excretion in the body before clinical application [2]